オンコセラピー・サイエンス(株)【4564】の掲示板 2018/11/16〜2018/11/26

これって、OTS964関連の論文！2018年10月24日！なかなかいいんじゃないの！
Mol Imaging Biol. 2018 Oct 24
RESULTS:
[18F]FE-OTS964 was successfully synthesized and validated in vivo as a PET imaging agent. The labeling reaction led to 15.1 ± 7.5 % radiochemical yield, 99 % radiochemical purity, and high specific activity. Chemical identity of the radiotracer was confirmed by co-elution on an analytical HPLC with a cold-labeled standard. In vivo PET imaging and biodistribution analysis showed tumor uptake of 3.06 ± 0.30 %ID/cc, which was reduced in animals co-injected with excess blocking dose of OTS541 to 1.40 ± 0.42 %ID/cc.
CONCLUSIONS:
[18F]FE-OTS964 is the first TOPK inhibitor for imaging purposes and may prove useful in the continued investigation of the pharmacology of TOPK inhibitors and the biology of TOPK in cancer patients.
KEYWORDS:
Glioblastoma; Molecular imaging; OTS964; PET; TOPK